Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Applied Genetic Tech's Shares Double on 6-Month X-Linked RP Study Results

Shares of Applied Genetic Technologies skyrocketed to a new 52-week high price after the company reported positive six-month data from its ongoing Phase 1/2 clinical study for treatment in X-Linked Retinitis Pigmentosa. The firm stated that the trial data suggests durable and ...
Streetwise Reports | January 10, 2020 |

Market News Report: February 24, 2020 - February 28, 2020

The financial markets have been fluctuating for most of the last week. Then on Friday we got worse-than-expected PMI numbers release, and corona virus fears reappeared ahead of the weekend. So markets went risk-off again. This week we will have some important economic data rel...
Paul Rejczak | February 24, 2020 |

Ovid Therapeutics Posts Positive Data from Phase 2 Seizure Reduction Trial

Ovid Therapeutics' shares are trading 25% higher today after the company reported positive initial data from its ENDYMION soticlestat phase 2 trial for patients with developmental and epileptic encephalopathies. Shares of Ovid Therapeutics Inc. (OVID:NASDAQ) are tra...
Streetwise Reports | September 25, 2019 |

Revolutionizing vascular grafting with a durable solution

Our next guest is a multi-technology biomedical company, focused on the development and commercialization of medical technologies. Marizyme Inc. (OTCQB:MRZM) has had its sights set on development of medical technology and products, one of which is DuraGraft. J...
Brieanna McCutcheon | September 27, 2023 |

Biopharma's Phase 3 Trial Results in Migraine 'Robust,' 'Impressive'

These topline data and next steps for the therapeutic are reviewed in a Ladenburg Thalmann report. In a Dec. 30 research note, analyst Matthew Kaplan reported that Ladenburg Thalmann increased its price target on Buy-rated Axsome Therapeutics Inc. (AXSM:NASDAQ) to $...
Streetwise Reports | January 6, 2020 |

Lydian International: Constructing Highly Profitable Gold Mine In Armenia

Interview With President & CEO Howard Stevenson Symbol: T.LYD
Commodity-TV | June 8, 2018 |

Important Economic News Calendar: November 25 – November 29, 2019

The global financial markets barely moved last week as economic data releases didn’t bring any meaningful surprises. So will the Thanksgiving holiday week bring volatility to the financial markets? Actually, we may see some market movements in the first half of...
Paul Rejczak | November 26, 2019 |

Avedro Shares Looking Up 35% with Glaukos Merger

Avedro Inc. and Glaukos Corp. announced that the firms' boards of directors have executed a definitive merger agreement. The all-stock deal is expected to close in Q4/19. After the markets closed yesterday afternoon, corneal modeling platform firm Avedro Inc...
Streetwise Reports | August 13, 2019 |

ArQule Shares Double on Proposed $2.7 Billion Tender Offer from Merck

ArQule Inc. shares traded more than 100% higher today after the company entered into definitive agreement to be acquired by a Merck subsidiary company for $20 per share. The deal is valued at $2.7 billion and is expected to close in the early part of Q1/20. This morni...
Streetwise Reports | December 10, 2019 |

Market News Report: January 27, 2020 – January 31, 2020

Not that much happened on the financial markets last week. Stocks extended their uptrend while the price of gold went sideways. Everyone seemed to be waiting for this week’s Wednesday’s FOMC Statement release. But there will be more interesting ...
Paul Rejczak | January 27, 2020 |
1 2 3 4 5 6 7 8 9 10 ...